Cystic Fibrosis Market Size, Share & Covid-19 Impact Analysis, By Drug Class (Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Retail Pharmacies & Drug Stores, Online Pharmacies, and Hospital Pharmacies), and Regional Forecast, 2020-2032

The global cystic fibrosis market size stood at USD 5.12 billion in 2019 and is projected to reach USD 62.57 billion by 2032, exhibiting a CAGR of 20.1% during the forecast period.

Cystic fibrosis (CF) is defined as a hereditary disease caused by mutation of genes. Genes control protein secretion of certain liquids in the body. This tends to thicken mucous and sweat by affecting various organs in the body. This condition alters the electrolyte transport system, causing cells to absorb sodium and water and leads to problems associated with glands that generate sweat and mucous. In addition to this, patients with this condition suffering from an increased infection in the upper respiratory tract and lower respiratory tract are also boosting the market growth. The increasing incidence of chronic cough, blood in sputum, and collapsed lungs is also propelling the growth of the market. Moreover, patients suffering from the disease also have problems with gastrointestinal system disorders owing to complications in absorbing proteins, fats, and vitamins, which is also impacting the growth of the market. Thus, the availability of diverse drugs for the treatment of respiratory and gastrointestinal infection and the availability of over the counter drugs for the treatment of reproductive system is expected to positively impact the market growth in the near future. Thus, increasing prevalence of the disease will influence the market growth during the forecast period.

Impact of COVID-19 on Cystic Fibrosis Patients

The sudden outbreak of the COVID -19 pandemic across the globe is also propelling market growth as these patients are at high risk of being infected by the virus. This, coupled with various other complications such as lung infections, inflammation of the pancreas, CF-related diabetes, and others, is strongly augmenting the cystic fibrosis market growth during the forecast period. The European Cystic Fibrosis Society (ECFS) is collecting and analyzing data of CF patients infected with COVID-19. The ECFS Patient Registry, in association with national cystic fibrosis registries, are collecting and reporting data to identify factors that forecast severity of COVID-19.

LATEST TRENDS

Request a Free sample to learn more about this report.

Increasing Availability of Advanced Treatment Options to Propel Market Growth

An increasing number of patients suffering from CF across the globe is triggering the market. Pharmacotherapy of CF has come up with various advancements in the treatment of this condition which is positively impacting the market growth. Furthermore, market trends present in the treatment of the disease are triggering the market growth, owing to the increasing number of pipeline candidates from major companies aiming towards therapeutic care. This in turn is influencing manufacturers to introduce advanced medication targeting CFTR protein abnormalities. Additionally, the launch of Ivacaftor / Lumacaftor, a potentiator that improves the lives of people suffering from the disease, is also augmenting the market growth.

Moreover, the increasing R&D activities and technological improvement by major companies is also aiding towards this market growth by introducing new products. For instance, the National Research Council launched cystic fibrosis diagnostic smart patch for early diagnosis of the condition.  This patch is digitally powered by wireless technology.

DRIVING FACTORS

Rising Prevalence of CF to Augment Market Growth

CF is emerging as the leading genetic disease across the globe. This often affects multiple organ systems of the body. According to the Cystic Fibrosis Patient Registry, it is estimated that more than 30,000 people are currently suffering from this condition in the U.S. and it is estimated that about 70,000 people are suffering from it across the globe. In addition to this, it is also noted that approximately 1,000 new cases of the disease are diagnosed every year. Thus, the rising prevalence of respiratory problems, gastrointestinal complications, and reproductive disorders in patients with CF is also expected to boost the demand for the treatment of the condition during the forecast period.

Moreover, the adoption of advanced treatment options for early detection is raising the patient population for better treatment this is anticipated to influence this market growth during the forecast period.

Presence of Potential Pipeline Candidates to Boost Market Growth

The introduction of drugs for the treatment of CF is on the new horizon which is boosting the growth of the market. The emergence of drugs that are targeting the defect in cells of people suffering from diseases is enhancing market growth during the forecast period. This treatment is anticipated to be life-changing for many patients is influencing the market growth. Furthermore, an increase in the prevalence of the disease is considered as the major driving factor of the market. This, in turn, is propelling the launch of newly formulated pipeline drugs required for the treatment of serious patients. In addition to this, many potential candidates are in their final stages of development and are projecting the growth of the market in the near future. For instance, Vertex Pharmaceuticals Incorporated announced positive results from their phase III clinical study on inhaled mannitol indicated for the treatment of mucociliary clearance. Along with this, technologically advanced devices used for various serious cases such as airway clearance techniques, mucous thinners, and others is poised to surge the cystic fibrosis therapeutics market during the forecast period.

RESTRAINING FACTORS

 High Adverse Effects of Drugs to Impede the Market Growth

Although the growth of the market is observed to be projecting over the years due to increase in awareness of the treatment options, rise in prevalence of the disease across the globe, increase in the launch of new drugs, and other developments there are some of the factors that are negatively influencing the market growth. The products have adverse effects such as upper respiratory tract infection, liver problems, chest pain, increase in blood pressure, and others that might hinder the market growth. In addition to this, the high cost of the treatment among CF patients suffering from a lung transplant, liver transplant, and others are also hindering the market growth. Furthermore, prolonged FDA approvals, product recalls, stringent regulations, and others are some of the factors that are negatively influencing the cystic fibrosis market.

SEGMENTATION

By Drug Class Analysis

To know how our report can help streamline your business, Speak to Analyst

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Dominated the Global Market

Based on the drug class, the market is segmented into cystic fibrosis transmembrane conductance regulator (CFTR), bronchodilators, mucolytic, and pancreatic enzyme supplement, and others. CFTR is considered to be a dominating market. Owing to its functions such as it improves the body’s function at the cellular level, which is considered to be slow, improves the function of CFTR protein, and others. Additionally, CFTR drugs also contributed towards the highest revenue generation during 2019 which has also positively influenced market growth. Furthermore, advanced therapies of triple combination drugs are also fueling the market growth in the near future.

Bronchodilators drugs are widely used by CF patients suffering from respiratory disorders and obstructive lung disease which is triggering the market growth. Moreover, the segment is considered to register the highest CAGR during the forecast period. Owing to an increased usage of these drugs in the treatment of muscle relaxation, airway clearance, and others. Mucolytic are considered to be important inhaled medications known as mucous thinners. The mucolytic drug named dornase alpha is mainly used in patients with the disease to improve airway clearance is aiding the market growth during the forecast period. Furthermore, pancreatic enzyme supplements also influence market growth. These are widely used in the treatment of gastrointestinal disorders in patients suffering from CF. An increase in potential pipeline candidates is also boosting the market. Others segment in drug class include antibiotics, anti-inflammatory, and others that are fueling this market growth during the forecast period.

Route of Administration Analysis

Oral Segment Dominated the Global Market

In terms of the route of administration, the global market is segmented into oral, and parenteral. Among these, the oral route of administration holds the largest market share owing to an increase in the adoption of oral drugs globally. Owing to the introduction of new formulation drugs that can be consumed easily without the risk of invasive procedures to obtain effective treatment. Furthermore, the parenteral drug segment is anticipated to register a relatively higher CAGR during the forecast period. Due to increased usage of parenteral drugs which include inhaled and injections. Thus, inhaled drugs are widely used by medical practitioners for patients suffering from high-risk respiratory disorders coupled with CF. Additionally, a rise in the use of injection for CF treatment is prompting the key players to focus on the large production of advanced formulation injection.

By Distribution Channel Analysis

Retail Pharmacies & Drug Store Segment is leading the Distribution Channel Analysis

Based on the distribution channel, the market is classified into retail pharmacies & drug stores, hospital online pharmacies, and hospital pharmacies. Retail pharmacies & drug stores are anticipated to dominate the market when compared with online pharmacies and hospital pharmacies segment in the near future. Due to the increase in partnerships with different medical professionals, healthcare centers, and others. Furthermore, the online pharmacies segment is also anticipated to emerge as the fastest-growing segment in the market. Owing to an increase in patients' preference towards the convenience of drugs, easy availability, and others are augmenting the growth of online pharmacies during the forecast period. Additionally, hospital pharmacies are expected to hold the least market share. Owing to an increase in patients suffering from CF tending to prefer medication through online pharmacies as it is a chronic therapy.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The global cystic fibrosis market in North America accounted for USD 3.89 billion in 2019. North America is anticipated to dominate the market globally. The factors responsible for the dominance of the market in the region is due to increase in CF cases, rise in patients suffering from various respiratory disorders influencing CF, increase in R&D activities, rise in healthcare expenditure, and others. Europe is considered to hold the second leading position in dominance next to North America during the forecast period. Owing to an increase in the prevalence of the disease, the rise in the adoption of advanced drugs for better outcomes, high disposable income, and others. Moreover, the Asia Pacific market is expected to offer numerous growth opportunities. . Due to the rise in geriatric patients, the rise in the development of healthcare facilities, high awareness associated with treatment, and others. Moreover, regions considered under the rest of the world include Latin America and Middle East & Africa. These regions are anticipated to experience lower growth owing to the unmet needs of healthcare, low prevalence of the disease in the region, low awareness associated with healthcare facilities, and others.

Moreover, the impact of COVID-19 pandemic across the globe is also impacting the growth of the market during the forecast period. The increase in the prevalence of respiratory disorders is leading the risk of CF. This, in turn, is boosting the key players present globally to focus on the development of new rugs for the faster recovery of the patients by reducing the mortality rate across the globe.

KEY INDUSTRY PLAYERS

Diverse Product Portfolio of Vertex to Aid Market Growth.

The key player dominating the market is Vertex Pharmaceuticals Incorporated due to diverse product portfolio and strong presence in CF treatment globally. Vertex Pharmaceuticals is Biotechnology Company which focuses on scientific innovations to develop transformative medicine for serious diseases. The company has multiple approved medicines for the treatment of CF. Along with various ongoing clinical studies and research program for treatment of underlying cause of CF, they have robust pipeline products for treatment of diseases such as sickle cell, type 1 diabetic mellitus, and others. Additionally, in terms of revenue Vertex Pharmaceuticals Incorporated is leading the market. Owing to its high revenue-generating products such as Orkambi and Symdeko which are indicated for the treatment of CF. Furthermore, Gilead Sciences, Inc. is anticipated to experience significant upscale across the globe during the forecast period, because of its product such as CAYSTON which are majorly Indicated to improve respiratory symptoms in CF patients.

LIST OF KEY COMPANIES PROFILED:

• Vertex Pharmaceuticals Incorporated 


• AbbVie Inc.


• Novartis AG


• Gilead Sciences, Inc.


• Mylan N.V. 


• Pfizer Inc. 


• Bayer AG


• Genentech, Inc.


• AstraZeneca


• Others

KEY INDUSTRY DEVELOPMENTS:

• October 2019 – AbbVie Inc. announced a collaboration with the Cystic Fibrosis Foundation to develop cystic fibrosis transmembrance conductance regulator (CFTR) potentiator compound licensed from the foundation.


• March 2018 – US FDA approved product named Symdeko manufactured by Vertex Pharmaceuticals Incorporated. The product is a combination of Tezacaftor and Ivacaftor majorly used in the treatment of CF.

REPORT COVERAGE

An Infographic Representation of Cystic Fibrosis Market

View Full Infographic

To get information on various segments, share your queries with us

The cystic fibrosis market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, drug class, route of administration, and distribution channel. Besides this, the market research report provides key insights into the market trends and highlights major industry developments such as mergers, acquisitions, and collaborations, new product launches, prevalence of CF, pipeline analysis. In addition to this, the report also focuses on the major driving factors and restraints that are influencing the market growth during the forecast period.

Report Scope & Segmentation